Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer : Halts Phase 3 Study on New Xarelto Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 08:44am CET
   By Sarah Sloat 
 

Bayer AG (>> Bayer) said late Thursday it halted a phase 3 study for the use of blood-thinning drug Xarelto because it didn't show improved efficacy compared with another treatment using aspirin.

The Navigate Esus study was testing Xarelto for the secondary prevention of strokes and systemic embolism in patients who recently had an embolic stroke of undetermined source.

Researchers stopped the trial early because the Xarelto and aspirin arms of the study showed comparable efficacy, and there was little chance of an overall benefit if it were completed, the German pharmaceutical and chemicals company said.

"While bleeding rates were low overall, an increase in bleeding was observed in the [Xarelto] arm compared to the low-dose aspirin arm," Bayer said.

Xarelto, also known as rivaroxaban, is a prescription anticoagulant which been approved for seven indications. The drug contributed just over 2.9 billion euros ($3.4 billion) in sales to Bayer's pharmaceutical division last year.

The drug was developed jointly by Bayer and Janssen Pharmaceuticals, a unit of Johnson & Johnson (>> Johnson & Johnson). It is marketed outside the U.S. by Bayer and within the U.S. by Janssen.

Write to Sarah Sloat at [email protected]

Stocks mentioned in the article : Bayer, Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
12/14 BAYER : Studies from Bayer Update Current Data on Nerve Tissue Proteins (A tripa..
12/13 BAYER : rivaroxaban submitted to U.S. FDA for approval in patients with coronary..
12/13DJPLANT IMPACT : Needs Extra GBP7 Million Funding by April, Hands up 'For Sale' Si..
12/12 Monsanto offers cash to U.S. farmers who use controversial chemical
12/08 EU regulators to warn Bayer about Monsanto bid
12/08 BAYER : Preventive Maintenance & service solution on existing Bayer/Medrad and A..
12/08 BAYER : J-- Preventive Maintenance & service solution on existing Bayer/Medrad a..
12/08 'Right steps' point to a healthier China
12/07 BAYER : Research Conducted at Bayer Has Provided New Information about Atrial Fi..
12/07 BAYER : Findings from Bayer Has Provided New Data on Liver Cancer (Exposure-resp..
More news
News from SeekingAlpha
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 Nektar Therapeutics down 1% premarket after Bayer bails on agreement to devel..
12/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 14, 2017
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/08 BLOOMBERG : Bayer to face EU objections to Monsanto deal in coming days
Financials (€)
Sales 2017 35 679 M
EBIT 2017 7 597 M
Net income 2017 6 179 M
Debt 2017 8 778 M
Yield 2017 2,46%
P/E ratio 2017 14,03
P/E ratio 2018 18,35
EV / Sales 2017 2,71x
EV / Sales 2018 2,48x
Capitalization 88 070 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 121 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER6.02%103 473
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386